The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
A Dose‐Response Study of Testosterone on Sexual Dysfunction and Features of the Metabolic Syndrome Using Testosterone Gel and Parenteral Testosterone Undecanoate
Abstract
ABSTRACT: The objective of this study was to observe the dose‐response effects of testosterone (T) treatment on symptoms of sexual dysfunction and the metabolic syndrome. Two cohorts of elderly men with late‐onset hypogonadism were followed over 9 months. Group 1, consisting of 28 men (mean age, 61 years; mean T level, 2.07 ± 0.50 ng/mL), received long‐acting T undecanoate (TU; 1000 mg); group 2, composed of 27 men (mean age, 60 years; mean T level, 2.24 ± 0.41 ng/mL), received T gel (50 mg/day) for 9 months. In patients treated with T gel, plasma T levels rose from 2.24 ± 0.41 to 2.95 ± 0.52 (statistically significant) at 3 months, 3.49 ± 0.89 (statistically significant) at 6 months, and 3.80 ± 0.73 ng/mL at 9 months (T level at 6 months was compared with T level at 3 months). With TU, plasma T levels rose from 2.08 ± 0.56 to 4.81 ± 0.83 (statistically significant) at 3 months, 5.29 ± 0.91 at 6 months, and 5.40 ± 0.77 ng/mL at 9 months. With TU, the plasma T levels were statistically significantly higher than with T gel With TU, there was a greater improvement in sexual symptoms and in symptoms of the metabolic syndrome. With both treatments, changes in waist circumference correlated with changes in total, low‐density, and high‐density lipoprotein cholesterol. Parameters of safety were not different between the 2 treatments. T administration had a beneficial effect on sexual dysfunction and symptoms of the metabolic syndrome in elderly men. The higher plasma levels of T generated with TU than with T gel were clearly more effective, indicating that there is a T dose‐effect relationship.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In our own studies, signs and symptoms of the metabolic syndrome improved substantially following administration of long-acting testosterone undecanoate (32, 35, 92) and improvements in glycemic control and lipids parallel improvements in body composition.”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [92]
Citations
Cites
Grundy, S. M., Brewer, H. B., Cleeman, J. I., Smith, S. C., & Lenfant, C. (2004) · Circulation · doi:10.1161/01.cir.0000111245.75752.c6 · Cited by 5,982
Ford, E. S. (2005) · Diabetes Care · doi:10.2337/diacare.28.11.2745 · Cited by 1,199
Testosterone dose-response relationships in healthy young men
Bhasin, S., Woodhouse, L., Casaburi, R., Singh, A. B., Bhasin, D., Berman, N., Chen, X., Yarasheski, K. E., Magliano, L., Dzekov, C., et al. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.6.e1172 · Cited by 967
Laaksonen, D. E., Niskanen, L., Punnonen, K., Nyyssönen, K., Tuomainen, T.-P., Valkonen, V.-P., Salonen, R., & Salonen, J. T. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1036 · Cited by 920
Definition of Metabolic Syndrome
Grundy, S. M., Brewer, H. B., Cleeman, J. I., Smith, S. C., & Lenfant, C. J. M. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000111245.75752.c6 · Cited by 739
Wang, C., Cunningham, G., Dobs, A., Iranmanesh, A., Matsumoto, A. M., Snyder, P. J., Weber, T., Berman, N., Hull, L., & Swerdloff, R. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032006 · Cited by 656
Kupelian, V., Page, S. T., Araujo, A. B., Travison, T. G., Bremner, W. J., & McKinlay, J. B. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1326 · Cited by 561
Association of Specific Symptoms and Metabolic Risks with Serum Testosterone in Older Men
Zitzmann, M., Faber, S., & Nieschlag, E. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0401 · Cited by 552
Vermeulen, A. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.5.1821 · Cited by 455
Niskanen, L., Laaksonen, D. E., Punnonen, K., Mustajoki, P., Kaukua, J., & Rissanen, A. (2004) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1462-8902.2004.00335.x · Cited by 275
Research works printed but not linked: 2
- 10.1210/jc.79.4.1173 · DOI · Paper page
- Organization World Health, 1992, Guidelines for the Use of Androgens in Men
Cited by
Sorted by citations
Items 101–132 of 132
The metabolic syndrome: when is testosterone treatment warranted
Gooren, L. J., Meryn, S., & Shabsigh, R. (2008) · Journal of Men s Health · doi:10.1016/j.jomh.2008.03.012 · Cited by 3
Self-citationTestosterone Therapy: Injectable Androgens
Yassin, A. A. (2023) · Springer eBooks · doi:10.1007/978-3-031-31501-5_15 · Cited by 2
Self-citationCardiometabolic outcomes of early onset hypogonadism in males
Peck, M., Connelly, P. J., & Lucas-Herald, A. K. (2025) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2025.102004 · Cited by 2
Late-onset hypogonadism or ADAM: treatment
Martits, A., Costa, E., Nardi, A., Nardozza, A., Facio, F., Faria, G., & Bernardo, W. (2014) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.60.05.005 · Cited by 2
Topical Testosterone Gel for the Treatment of Male Hypogonadism
Udeoji, D. U., Phan, A., Katsiyiannis, P., Willix, R., & Schwarz, E. R. (2012) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s7348 · Cited by 2
Permpongkosol, S., Ratana-olarn, K., Tantiwong, A., Tantiwongse, K., & Kongkanand, A. (2013) · Open Journal of Urology · doi:10.4236/oju.2013.33026 · Cited by 1
Can the administration of testosterone to men with late-onset hypogonadism be discontinued?
Gooren, L. J. (2008) · Journal of Men s Health · doi:10.1016/j.jomh.2008.09.005 · Cited by 1
Self-citationKarampela, D. S., Giannopoulou, P. C., Νάτσος, Α., Margos, N. P., Zvintzou, E., & Kypreos, K. E. (2022) · Androgens Clinical Research and Therapeutics · doi:10.1089/andro.2022.0010 · Cited by 1
Androgens and Vascular Function
Ferrer, M. (2011) · InTech eBooks · doi:10.5772/18603 · Cited by 1
Recent perspectives on the age-related decline of testosterone
Gooren, L. J. (2008) · Journal of Men s Health · doi:10.1016/j.jomh.2007.12.003 · Cited by 1
Self-citationPredictive Factors of Efficacy Maintenance after Testosterone Treatment Cessation
Park, M. G., Yeo, J. K., Park, S., Na, W., & Moon, D. G. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8020151 · Cited by 1
Gheorghiu, M. L. (2008) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2008.59 · Cited by 1
Ajani, O. S., Obiechefu, C. H., & Ake, A. S. (2025) · Tropical Journal of Phytochemistry and Pharmaceutical Sciences · doi:10.26538/tjpps/v4i2.1 · Cited by 1
Figueiredo, P. R. L., Martins, M. R. A., Montenegro, R. M., Albano, M. F., & Montenegro, R. M. (2009) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302009000800018
Therapeutic Potential of Testosterone Gels
Lunenfeld, B., & Oettel, M. (2009) · Aging Health · doi:10.2217/ahe.09.6
Testosterone Undecanoate: A Review
Lyngdorf, P. (2012) · Aging Health · doi:10.2217/ahe.12.26
Ian Eardley, C. (2008) · Journal of Men s Health · doi:10.1016/j.jomh.2008.03.011
Júnior, A. D. S., Clapauch, R., & Buksman, S. (2009)
Elliott, J. (2016) · uO Research (University of Ottawa) · doi:10.20381/ruor-5176
Testosterone and Risk Factors in the Metabolic Syndrome: Implications for Erectile Dysfunction
Guay, A. T., & Traish, A. M. (2011)
Alves-Lopes, R., Neves, K. B., Pestana, C. R., Queiroz, A. L., Zanotto, C. Z., Chignalia, A. Z., Lucisano-Valim, Y. M., Silveira, L. R., Curti, C., Tostes, R. C., et al. (2014)
Testosterone Therapy: Injectable Androgens
Yassin, A. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-46086-4_12
Self-citationAndrogensubstitution des älteren Mannes
Jockenhövel, F. (2010) · Elsevier eBooks · doi:10.1016/b978-3-437-24680-7.10050-9
Effects of testosterone levels on mortality and cardiovascular risk in men with Type 2 diabetes
Muraleedharan, V. (2018) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Albayrak, A. T., & Şerefoğlu, E. C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816665-9.00007-x
Testosterone and the aging male: To treat or not to treat?
Baina, J. (2010)
The anti-inflammatory effects of testosterone on atherosclerosis
Bateman, L. (2020) · Sheffield Hallam University · doi:10.7190/shu-thesis-00351 · Cited by 1
Zitzmann, M. (2010) · Elsevier eBooks · doi:10.1016/b978-3-437-24680-7.10044-3
Yang, K., Jiang, H., & Zhang, X. (2023) · Journal of Men s Health · doi:10.22514/jomh.2023.036
Testosterontherapie: injizierbare Androgene
Yassin, A. A. (2024) · Springer eBooks · doi:10.1007/978-3-031-65245-5_15
Self-citationObesity-Related Male Sexual Dysfunction: Pathophysiology and Clinical Implications
Albayrak, A. T. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1017181
Menafra, D., de Angelis, C., Garifalos, F., Chiodini, P., Verde, N., Piscopo, M., Galdiero, G., Fraia, D. A. D., Mazzarella, A., Paola, N. D., et al. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-03037-5
Metadata
- Authors
- Saad, F., Gooren, L. J., Haider, A., & Yassin, A.
- Affiliations
- Gulf Medical University (AE)
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Corresponding author
- Saad, Farid
- Venue
- Journal of Andrology
- Publisher
- Wiley
- Published
- 2008-01-02
- Volume
- 29
- Issue
- 1
- Pages
- 102-105
- ISSN
- 0196-3635 (ISSN-L)
- 1939-4640
- OpenAlex
- W2081710331
- Cited by
- 132
- References
- 22
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 2 · 2023: 2 · 2022: 4 · 2021: 1 · 2020: 2 · 2019: 6 · 2018: 5 · 2017: 5 · 2016: 4 · 2015: 6 · 2014: 17 · 2013: 7 · 2012: 8
- FWCI
- 11.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Andrology (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- testosterone, testosterone undecanoate, testosterone gel, andropause, sexual dysfunction, metabolic syndrome, dose-response relationship, older men, plasma testosterone, waist circumference, lipoproteins, testosterone replacement therapy
- MeSH terms
- Administration, Topical, Body Weight, Dose-Response Relationship, Drug, Gels, Humans, Injections, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Sexual Dysfunction, Physiological, Testosterone, Triglycerides, Cohort Studies, Metabolic Syndrome, Testosterone Congeners
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
